Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 742)
Posted On: 02/22/2025 8:15:39 AM
Post# of 155869
Posted By: My69z
MDR paper / 2023 ART stop & 350mg LL:

Results:
*52 participants were enrolled (25 leronlimab and 27 placebo)
*Leronlimab was generally well tolerated with no drug-related SAEs reported.

Conclusions:
*Leronlimab resulted in significantly reduced plasma HIV-1 within one week after addition to failing ART.
https://journals.lww.com/jaids/abstract/9900/...1.602.aspx

ART stop & 350mg LL to viral breakthrough:
*Overall Number of Baseline Participants: 43
*Adverse events were collected for a total of 18 weeks, from treatment visit 1 (Post Rx) to treatment visit T14 (Week 14) and through the follow up period, every 2 week for total of 4 weeks.

*Serious Adverse Events: 1/43
Nervous system disorders: 1
Transient Ischemic Attack

Principal Investigator:Jacob Lalezari, MD
https://clinicaltrials.gov/study/NCT02175680?...ts&a=9

The internet told me TIA can be related to a blood clot & sign of potential stroke. Usually resolves itsself in minutes to maybe 24 hours. But as usual, no LL post-trial SAE's.

ART stop: 350mg was significant.
MASH: 350mg was significant.
CCL4: 350mg was significant.
MDR: 350mg was significant.













(8)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site